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Abstract 
Elastomeric pumps are widely used to facilitate ambulatory chemotherapy, and studies have 
shown that they are safe and well received by patients.  Despite these advantages, their end of 
infusion time can fluctuate significantly.  The aim of this research was to observe the 
performance of these pumps in real practice and to evaluate patients’ satisfaction. This was a 
two-phase study conducted at three cancer units over 6 months. Phase-1 was an observational 
study recording the status of pumps at the scheduled disconnection time and noting   
remaining   volume   of   infusion.   Phase-2   was   a   survey   of   patients   and   their 
perception/satisfaction.  Ethical approval was granted. 92  cases  were  observed  covering 50  
cases  disconnected at  hospital  and 42 disconnected  at home. The infusion in 40% of 
hospital disconnection cases was slow with patients arriving at hospital with unfinished 
pumps.  58%  of  these  had  an  estimated  remaining  volume which exceeded  10mL with  
35%  exceeding  20mL.  In 73% of these cases, and regardless of the remaining volume, the 
patient was disconnected and the pump was discarded. 
To conclude, the performance of pumps varied, which affected nurse workload and patients’ 
waiting-times.  A  smart  system  is  an  option  to  monitor  the  performance  of  pumps  and 
to predict  their accuracy. 
 
Keywords:  Ambulatory Chemotherapy,   Ambulatory Infusion Pump,   Elastomeric Pumps, 
Safety, Colorectal Cancer, Fluorouracil, 5-FU, FOLFIRI, FOLFOX. 
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Introduction 
Background:  
With the advent of elastomeric pumps (EPs), ambulatory chemotherapy (AC) has become the 
preferred  choice  of  treatment  for  many  regimens  (Gorski  &  Grothman  1996). 
Ambulatory chemotherapy  services  have  had  a  significant  positive  impact  on  patients’  
quality  of  life (QoL),  staff workload and NHS costs (Dougherty et al.  1998). Despite  these  
advantages,  the  accuracy  of  infusion  time  of  these  pumps  can  fluctuate significantly 
and is dependent  on several factors such as  temperature and viscosity (Salman  et al.   2013).    
With  many  different  environmental  factors  influencing  the   accuracy  of  these pumps,  it  
is  nearly  impossible  to  model  the  exact  environment  that  duplicates  conditions 
experienced  during  standard  clinical  practice.  Fluctuations in elastomeric pumps 
performance may affect the total chemotherapeutic dosage delivery time, patients’ waiting 
time, satisfaction and quality of care. Therefore, there was a need to evaluate the performance 
of these pumps in real practice.  
 
To date, the reliability and accuracy of EPs in laboratory based settings has been investigated 
in several previous studies (Chung et al. 2001; Thiveaud et al. 2005; Ackermann et al. 2007; 
Wang et al.  2012).  
However, there are very few studies evaluating EP performance in practice. Hardy et al (15)  
investigated the  accuracy of  6  ambulatory infusions,  5 electric and one elastomeric pump. 
The elastomeric pump (Baxter®) was the least accurate pump with a relative error in infusion 
time of -5 to +13%. It was demonstrated that patients preferred the Parker-Strato 2100, an 
electronic pump (Hardy et al.  1995). Cassano-Piché et al surveyed clinicians regarding 
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patients receiving AC and including the number  of   incidents  related  to  EPs  (Cassano-
Piché  et  al.   2012).  Findings  of   this  study reported a  total  of  46 incidents  (out  of  213 
incidents),  such  as  pumps  failure and incorrect flow rate, during the administration of 
medications using EPs (Cassano-Piché et al. 2012). 
Impact on Clinical Practice: 
The findings of these studies left many unanswered questions related to the accuracy of EPs 
in standard clinical practice. Would the flow rate of pumps fluctuate more in practice than 
that specified by the manufacturer? Would the variation in flow rate of pumps affect patients’ 
satisfaction, waiting times or the overall treatment management? Since the performance of 
EPs is unpredictable, the end of infusion time can vary resulting in patients arriving for 
disconnection with unfinished pumps. Nurses may then ask patients with unfinished pumps to 
wait for hours not knowing for certain if the pumps will complete the infusion at all. To date, 
AC has not been evaluated from this point of view as previous studies have mainly focused 
on QoL in relation to receiving treatment at home and not the effect of variation in pumps 
(which can increase patients waiting times). Fluctuations  in  elastomeric  pumps  
performance  may  therefore  affect  patients’  satisfaction and  quality  of  care.  Previous  
studies  have  reported  that  waiting  times  are  a  major factor affecting patient  satisfaction  
(Anderson  et al.  2007;  Dansky &  Miles  1997;  Michael  et al. Leddy  et  al.).  . Dansky 
and Miles (1997) have suggested that informing the patients how long they have to wait may 
improve the patients’ satisfaction (Dansky & Miles 1997). 
Current Practice: 
This audit was based on the hypothesis that if the performance of elastomeric pumps varies, 
patients might have to wait in the  medical day unit (MDU) for the pumps to finish eluting or  
go back home and then return to the MDU the next day. Patients who normally have their 
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pumps disconnected at home by a district nurse, have to rearrange their appointments, which 
inconveniences both patients and nurses. 
The  regimens  evaluated  in  this  study  were  FOLFOX  and  FOLFIRI  for  the  treatment  
of colorectal cancer, which is the most common cancer treated using AC-EPs in the UK 
(Mabro et   al.   2006;   SEESURN   2012;   Field   et   al.   2008).   Fluorouracil   (5-FU)   is   
currently administered,  as  a  48  hour  continuous  infusion  using  EPs,  as  part  of  the  
FOLFIRI  and FOLFOX-6 regimens (Wang et al. 2007; Seifert et al. 1975).  
Fluorouracil  
5-FU is known to have a short half-life of 5-20 minutes in plasma, and a narrow therapeutic 
window (Undevia et al. 2005; Blaschke et  al.  2011; Ackermann et al. 2007).  It was  
reported  by Blaschke et  al  (2011) that when  calculating the  ideal  dosage  of  5-FU,  
minimising toxicity while  maintaining optimum therapeutic  effect   remains  challenging.   
They found 5-FU   to   have   a  narrow therapeutic window of 18-25 mg/h/l and that its 
plasma concentration was affected by higher and lower doses (Blaschke et al. 2011). Thus, 
depending on each regimen and the chemotherapeutic agent’s  pharmacokinetics  properties  
(half-life),  variation  in  the  performance  of elastomeric pumps  may  therefore affect the 
treatment outcome. 
For the above reasons, the aim of this audit was to evaluate the performance and accuracy of 
elastomeric pumps in standard clinical practice and the action taken with unfinished pumps. 
The audit also aimed to evaluate patient waiting times to disconnect their pumps, patients’ 
satisfaction and perception of current elastomeric pumps and overall AC services. 
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Materials and Methods 
This two-phase audit observed and evaluated patients receiving AC (5FU infused via a  48 
hour elastomeric pump) at three gastrointestinal medical day units (MDU), one at each of the 
three Royal Marsden NHS Trust  sites. 
Both phases were conducted from September 2013 to March 2014. Approval to conduct both 
phases was sought and granted from the Clinical Audit committee at the Royal Marsden NHS 
Trust.  
a.    Phase I 
Phase I was an observational cross-sectional study. A data collection sheet was designed to 
capture the required data.  Patients were observed at connection and disconnection in the 
MDU and the remaining volumes were visually estimated by the researcher using a pictorial 
guide produced by the researchers).  Some patients were observed several  times counting 
each treatment cycle/disconnection time as a case study.  The observational tool was divided 
into 5 sections (A-E) as shown in Table 1. Ay further information gathered from the patients 
was also considered such   as   reasons   behind   unfinished   pumps   i.e.   Cold   weather,   
blocked   catheter   etc. Furthermore,  any  information  given  to  patients  by  the  nurses  
regarding  their  unfinished pumps  was  recorded 
b.    Phase II 
Phase  II  was  a  survey  of  the  encountered  patients’  perceptions on elastomeric pumps.  
The questionnaire was designed to capture all relevant data, and it was divided into 5 sections 
(A-E).  
•      Part A: Patient experience with pump (Figure 1), this includes  
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o   The number of times of using elastomeric devices  
o   Previous pump performance i.e. if the pump finished on time, leakages or stopped 
working. 
•      Part B: Hospital policy regarding unfinished pumps covering the patients’ previous 
experience. 
•      Part C: Any incidents with pumps such as leakages inside or outside the pump using 
closed ended questions.  
•      Part D: Assessment of patient perception and satisfaction with the performance of 
elastomeric pumps. 
•      Part E: This section was designed to provide the patients with the space to reported any 
other incidents or suggest improvements.  
 All patients observed in Phase I were asked to complete the survey.  
c.    Data Analysis 
Confidentiality across both phases was maintained.  All data collected from both  phases I & 
II were  anonymised  and  analysed  using  Microsoft  Excel  (2010)  software. Infusion time 
duration was the dependent variable that was measured within this study.  Mean, standard 
deviation, median and percentage of incidents were also calculated.  
The data collected via the survey was analysed using descriptive statistics. Results collected 
from Phase I and II were synthetized for overall conclusions and recommendations.  
 
 
12 
 
Results 
For Phase I, 92 cases were followed covering 50 cases disconnected at MDU and 42 at home 
by district nurses. For Phase II of the study, 65 patients completed the questionnaire covering 
500 cases of using the elastomeric pumps. Equal distribution between male and female 
patients was observed with a median age of 64 and a range from 29-88 years old. FOLFIRI 
and FOLFOX, the two major therapies monitored, had a median cycle of treatment per 
patient of 4 and a range of 1-12 cycles. 66% of cases had peripherally inserted central 
catheter (PICC) lines while the remaining 34% had Port lines. 
 
Phase I results and the performance of elastomeric pumps 
From the fifty disconnections observed at the MDU (Table 2), 25 (50%) finished on time 
with a margin of ± 59 minutes, 5 (10%) finished faster (<48 hours) and 20 (40%) needed 
more time as the infusion was slow (> 48 hours).  For the fast pumps, 3 cases (6%) finished 
earlier than expected by approximately 2  hours  and  2  cases  (4%) had  an  unknown  
infusion time.  
The  slow  pumps (40%  of  cases)  were  either  allowed  to  finish  infusing or  discarded 
(summarised below).  The former were left to infuse for an average of 5 extra hours with a 
range of 1 to 18 additional hours. 
 The remaining infusion volumes at approximately 48 hours varied with 43% of the slow 
pumps having 10 mL or less (Total planned infusion volume= 120 mL, Table 2). The 
remainder of the slow pumps (57%, Table 2) had more than 11 mL remaining with 19% 
having more than 30 mL. During the observations, it was noted that the   remaining volumes 
in the unfinished pumps were often under- estimated by the nursing staff. Furthermore, the 
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nurses fed back estimations to the patients and recorded the   infusion as complete in the 
patients’ records. No leakage incidents were observed, however, high condensation levels 
were often observed between the plastic rigid container and elastic reservoir. 
Observing  the  performance  of  elastomeric  pumps  disconnected  at  home (n=42)  was  not 
feasible. Therefore,  patients  were  phoned  48  hours  after connection  to  check  on  the  
status  of their pumps. Patients reported over the phone that 48% of cases were disconnected 
on time (48 hours), 47% of cases were disconnected after 48 hours (average= 50 hours) and 
only 5 % of cases were disconnected before 48 hours (average of 1 hour earlier).  
Action taken with unfinished pumps  
It was observed that there was no  formal  policy guiding the actions of health professionals  
regarding unfinished pumps. In fact, before conducting this audit, this was not recognised as 
an issue of concern. Results  revealed  that  pumps  with  over  20  mL  of  infusion  
remaining  were  generally considered as unfinished by the nurses.  Due to the absence of a 
policy, the nursing staff had various approaches towards unfinished pumps (Table 2). The 
different approaches that were observed are as below: 
 65% of these pumps were discarded immediately. 70% of these pumps had less than 
20 mL of infusion remaining, however the rest of the pumps had up to 30 mL of 
infusion remaining) 
 In 15% of the cases, the patient was asked to wait in the MDU  to allow the pump to 
infuse further 
 In 10% of the cases, the patient was sent home and asked to come back the next day 
 In 10% of the cases, Patient was given advice over the phone. 
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Patient waiting times  
Some of patients returning after 48 hours with unfinished pumps were asked to wait either at 
 MDU: 15% of unfinished  pumps 
Patients’  waiting  time  for  these  incidents  was  in  the  range  of  30  –  60  minutes  with 
approximately 20 mL left  over infusion. 
 Home: 20% of unfinished  pumps 
Patients who were sent home and asked to return to the MDU had their pumps connected for 
64-68 hours. This translates into an additional 16-20 hours for their infusion to complete. 
Furthermore, one of the pumps was discarded after 16 hours of delay   with more than 30% of 
the infusion remaining. Consequently that patient did not receive the full desired dose even 
after the long wait. 
Phase 2  
Of the 65 patients who completed the survey, reported the infusion did not finish at the 
expected time in 21% of the cases. Of these, 17% were due to slow infusion rate; the 
remaining 4% were due to either fast infusion rate (3%) or to pump failure (1%).  
For 52% of the cases, patients came back to the hospital to disconnect their pumps. For 42% 
of the cases, patients stayed at home and their pumps were disconnected by the district nurses 
while the remaining 4% of the cases patients disconnected their pumps by themselves.  
Furthermore, none of the patients s experienced any leakage inside or outside the elastomeric 
pump and there were 5 cases where the pump stopped working completely.  
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For patient satisfaction, the participants were asked to rate their satisfaction with the 
elastomeric pumps and the service in general. 34% indicated they were satisfied while 64% 
indicated they were very satisfied.  
Moreover, patients were asked to provide more information about how they are handling their 
pumps while they are at home and during their daily routine activities. These are summarised 
in Table 3. 
Discussion 
This paper demonstrates the performance and accuracy of elastomeric pumps in practice for 
the treatment of colorectal cancer. The performance of elastomeric pumps was shown to be 
variable affecting the total dose administered to the patients (in the case of slow pumps) as a 
significant percentage of unfinished pumps were discarded.  
Chemotherapeutic dosage infusion time in practice:  
40% of the observed disconnections were slow pumps with a 2-38% deviation in elution time 
in practice. This is significantly higher than the manufacturer specification of 10% (Baxter 
clinician guide, 2014). In 57% of the unfinished infusions, the pumps were discarded 
translating into  patients not receiving the planned  dose  ,  (loss of  4-25% of the planned 
dose).  With a direct concentration-response rate association, keeping the level of 5-FU in the 
plasma within the therapeutic window is crucial for optimal survival rates (Gamelin et al. 
1996; Gamelin et al.  2008; Gamelin et al.  1998; Ychou et al.  2003). It was reported 
previously that the treatment outcome might be affected with a 15% reduction in the 
chemotherapy dose (Sewell 2006; Bonadonna et al.  1995).  
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Impact of infusion time variation in practice 
Variation in the pumps’ performance also affected both nurses’ workload and patients’ 
waiting times. Nurses had no formal policy to guide their response to unfinished infusions at 
48 hours. Moreover, the nurses’ visual inspection used to estimate the volume of left over 
infusion was underestimating the actual volume. 
Slow infusion rate (infusion more than 48 hours) 
Slow infusion rate translated into  patients receiving less than 75% of the prescribed 5-FU 
dose which is beyond the acceptable 10% margin of error (Sewell 2006; Plumridge & Sewell 
2001).  These cases resulted in patients receiving sub-therapeutic dosing. 
Fast infusion rate (infusion less than 48 hours) 
There was  a challenge  with recording fast  pumps as patients  were  returning to  MDU  
before their scheduled appointments with  already finished pumps so the exact  infusion time  
could  not  be recorded.  These cases were still considered as fast, however as no attempts 
could be made to estimate the end of infusion time the pumps were categorised as <48 hours-
unknown. 
Feedback from patients disconnected by district nurses  
It is important to note that in cases of late pump disconnection (47%) this may not be because 
of the slow infusion; it could be that the pump infused on time but the district nurse arrived 
few hours later. It was hypothesised that the district nurses estimation of the remaining 
infusion may well be similar to those nurses estimation in the MDU. Therefore, pumps 
regarded as finished may have had infusion remaining when disconnected. 
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Comparison between Phase I and II  
Findings from the patients’ questionnaire contradict those of observational study. Results of 
the patients’ questionnaire report fewer incidents of elastomeric pumps not finishing on time 
(both fast and slow pumps). The percentage  of  pumps finishing  after 48 hours was 
approximately halved when the results were reported by patients (Phase II) as opposed to 
observed at disconnections (phase I). This might be due to the under-estimation of the 
remaining infusion volume by the nurses. Therefore, patients may have reported unfinished 
pumps as finished basing their conclusions on the received positive response regarding their 
pumps performance. 
Smart system 
The survey of current AC services demonstrated a high percentage of patient satisfaction. 
However with the many factors influencing the performance of these pumps and the impact 
on the treatment management, there is a need for innovation in this field. Currently, a 
prototype “smart” system has been developed that is capable of  using digital imaging to 
evaluate the performance   of   these   pumps   in   real-time. This provides feedback to  both   
patients   and  healthcare professionals in an effort to achieve a more proactive approach 
capable of detecting significant alterations in infusions early on (Salman et al, 2015) 
Implications for Practice and Conclusion 
The findings of this audit have highlighted areas where AC services can be improved. To 
address this in practice, several actions can be taken such as raising awareness amongst 
health professionals involved in AC services and implementing a policy for action to be taken 
in the event of pumps not finishing at 48 hours. This should also be coupled with an 
educational campaign for health professionals. This can include practical approaches to 
estimate remaining volume in the pump such as using a poster/handout/memo with pictures 
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of the pump filled with different volumes of solution or the use of balances to weigh the 
pumps.  It is also recommended to update the patient information leaflet with a new section 
entitled “Is your infuser working?”. This section includes pictures of the pump with known 
volumes of left over infusion and what to do in the cases of interrupted infusions. It could 
also be printed as a flyer and placed with the pump in the infusion bag. 
Limitations 
Even though this audit highlighted an unreported problem with unfinished infusors being 
discarded, a bigger study with a larger sample size, different type of infusors and longer 
observation would have provided more insight into the problem. Moreover, the visual 
estimation of the remaining volume used in the methodology is not precise and using a 
balance would have circumvented this limitation. This was addressed in a follow up study 
reported elsewhere. 
This paper has summarised the findings of a clinical audit that highlighted a concern with 
ambulatory chemotherapy where a significant proportion of patients not receiving their 
planned doses. The issue is further compounded by the fact that it is not documented in the 
patient notes nor is the prescriber notified. This concern should also be investigated in other 
uses of Eps such as antimicrobials. Raising awareness about this discrepancy may help 
address the problem through institutional policies, health professional and patient education. 
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 Table2  
Infusion time observed  Percentage observed (%)  
Infusion finishing on time  50 
Infusion finishing before 48 
hours (fast pumps) 
10 
Infusion finishing after 48 
hours (slow pumps) 
40 
Infusion failure  0 
Infusion Leakage  0 
Volume remaining in the 
pumps at disconnection 
time (mL) 
Delivered 
dose 
Percentage 
observed (%) 
< 5  > 96 15 
5-10  < 96 27 
11-20  < 91 23 
21-30  < 83 15 
> 30 mLs < 75 19 
 
 
 
Table 3 
 
Patients’ activities and handling of elastomeric pumps Percentages 
(%) 
Patients sleeping with the pump while keeping it in the bag around their waist 26 
Patients sleep with the pump near pillow 11 
Patients sleep on the pump 5 
Patients  shower with the pump 9 
Home temperature can go above 25°C  3 
Home temperature below <10°C at night 2 
Patient know/record temperature of house 25 
 
 
